IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News / Institutional news

  • 23/11/2020 - Institutional news

    The BAPP renews its TECNIO accreditation

    The BAPP (Bioanalysis, Proteomics and Pharmacology), a collaborative centre from the Hospital del Mar Medical Research Institute (IMIM) and the UPF, has obtained the TECNIO accreditation for the period 2020-2023.  This seal, which the centre had already obtained in previous editions, is awarded by the Government of Catalonia through ACCIÓN. It identifies and raises the profile of centres with high scientific and technical capacities that are considered to be developers of differential technologies and which are leaders when it comes to transferring their knowledge and technologies to industry. The BAPP is a multidisciplinary centre specialising in research and service activities in four sectors: pharmacology, neurosciences, peptide chemistry, and bioanalysis. Its main focus is the development of new drugs for human and veterinary use.  It comprises the Integrated Pharmacology and Systems Neuroscience (Farmacologia Integrada i Neurociència de Sistemes; FINS) research group of the IMIM-Hospital del Mar, on the one hand, and the Proteomics and Protein Chemistry research group from the UPF on the other.

    Més informació "The BAPP renews its TECNIO accreditation"

  • 24/07/2020 - Institutional news

    IMIM, one of the Health Research Institutes to receive an ISCIII Responsible Research and Innovation Award

    In the first edition of the Responsible Research and Innovation (RRI) in Health Awards organised by ISCIII and promoted as part of the European project ORION  (Open Responsible research and Innovation to further Outstanding kNowledge) three proposals from three different Health Research Institutes (HRI) have been honoured out of a total of 26 proposals received. One of these three proposals is an IMIM project: The name of the successful project is "Co-creation and citizen participation in the design of the PENSA Study on the Prevention of Cognitive Impairment in People with Subjective Memory Complaints". Presented by Natàlia Soldevila and Laura Forcano from the Integrated Pharmacology and Systems Neuroscience research group at the IMIM, this work stands out for its application of citizen participation in the design of a clinical trial, an added value that allows the project to be reoriented to better adapt to the needs and expectations of the participants.

    Més informació "IMIM, one of the Health Research Institutes to receive an ISCIII Responsible Research and Innovation Award"

  • Institutional news

    The IMIM becomes part of the European Consortium EATRIS to promote translational medicine

    The IMIM Clinical Metabolomics Platform led by Dr. Oscar J. Pozo, from the IMIM Integrated Pharmacology and Systems Neuroscience Research Group, has become part of the EATRIS consortium, the European infrastructure for translational medicine, as part of the biomarker platform. This means that the IMIM is now part of a consortium comprising more than 80 prestigious European institutes that is aiming to establish synergies between healthcare researchers by providing them with the most advanced technologies and the experience needed to make headway in translational medicine. EATRIS is a European Research Infrastructure Consortium (ERIC) whose main objective is to advance translational medicine.  Translational research is a highly multidisciplinary and complex undertaking.  One of the greatest challenges in innovation is to understand which steps are necessary and the most appropriate technology and knowledge for taking these steps.

    Més informació "The IMIM becomes part of the European Consortium EATRIS to promote translational medicine"

  • 09/10/2015 - Institutional news

    IMIM receives funding from the IOC to conduct innovative anti-doping research

    In its mission to protect and promote clean athletes, the International Olympic Committee (IOC) is financing and backing seven innovative research projects in the fight against doping, which include a project by Dr Jordi Segura, coordinator of the research group on bioanalysis and analytic services at IMIM. The project is entitled ‘Developments for improving compliance with blood testing, a fundamental but minimally implemented tool in doping control (EASY BLOOD)’ and its purpose is to explore and validate the applicability of the use of new matrices (dried blood spot and capillary sampling) to replace the blood sample collection methods that are currently used to control doping (which are whole blood, plasma and serum). The seven projects funded are from Australia, Spain and the United Kingdom and were selected from among the applications received from throughout the world in the two calls opened by the IOC.

    Més informació "IMIM receives funding from the IOC to conduct innovative anti-doping research"

  • 20/12/2012 - Institutional news

    A delegation from the China Anti-Doping Agency visits IMIM

    On Friday the 14th of December, the Bioanalysis and Analytical Services Research Group from IMIM (Hospital del Mar Medical Research Institute) was visited by a delegation from the China Anti-Doping Agency (CHINADA). This visit is framed within the longstanding collaboration between the Anti-Doping Control Laboratory and IMIM and the Beijing Anti-Doping Laboratory and the China Anti-Doping Agency for research projects on doping control in sports.

    Més informació "A delegation from the China Anti-Doping Agency visits IMIM"

  • 14/10/2011 - Institutional news

    The Pan American Games begin: The Anti- Doping Lab of IMIM moves to Mexico.

    During approximately one month, some twenty professionals of the Anti-Doping Control Laboratory of the IMIM (Hospital del Mar Research Institute) will be moving to Mexico to carry out the tests for anti-doping control at the games.

    Més informació "The Pan American Games begin: The Anti- Doping Lab of IMIM moves to Mexico."

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact